Revvity, Inc. (RVTY)
Revvity, Inc. provides comprehensive solutions across the diagnostics, life sciences, and applied services markets. The company operates through two segments, offering a range of products and services from research tools to diagnostic testing.
Company Overview
Revvity, Inc. empowers scientific advancements and diagnostic accuracy with its diverse portfolio of life science and diagnostic solutions, offering investors a unique opportunity to capitalize on the growing demand for innovative healthcare technologies and precision medicine, driven by a strong market position and strategic acquisitions.
Investment Thesis
Revvity presents a compelling investment opportunity due to its strategic positioning in the growing life sciences and diagnostics markets. With a current P/E ratio of 47.59 and a profit margin of 8.5%, the company demonstrates solid profitability and growth potential. Key value drivers include the increasing demand for precision medicine, advancements in genomic research, and the expansion of diagnostic testing capabilities. The company's diverse product portfolio and global reach provide a stable revenue base, while ongoing investments in R&D and strategic acquisitions are expected to fuel future growth. The company's dividend yield of 0.28% provides a small return for investors. The company's beta of 1.09 indicates market correlation.
Key Highlights
- Market Cap of $11.79B reflects Revvity's significant presence in the healthcare sector.
- P/E Ratio of 47.59 indicates investor expectations for future earnings growth.
- Gross Margin of 53.1% demonstrates efficient cost management and pricing power.
- Profit Margin of 8.5% shows the company's ability to convert revenue into profit.
- Dividend Yield of 0.28% provides a modest income stream for investors.
Competitors
Strengths
- Diverse product portfolio across life sciences and diagnostics.
- Strong brand recognition and reputation.
- Global presence and established distribution network.
- Experienced management team and skilled workforce.
Weaknesses
- High P/E ratio may indicate overvaluation.
- Dependence on research and development for future growth.
- Exposure to regulatory changes and healthcare reforms.
- Competition from larger and more specialized players.
Catalysts
- Upcoming: New product launches in the diagnostics segment, expected in Q3 2026, could drive revenue growth.
- Ongoing: Strategic partnerships with pharmaceutical companies to develop companion diagnostics.
- Ongoing: Expansion of genomic services offerings to capture a larger share of the precision medicine market.
- Upcoming: Potential acquisitions of companies with complementary technologies or market access by Q4 2026.
Risks
- Potential: Economic slowdown could reduce research funding and demand for diagnostic testing.
- Potential: Regulatory changes in healthcare could impact pricing and reimbursement.
- Ongoing: Competition from larger and more specialized players in the life sciences and diagnostics markets.
- Potential: Technological obsolescence could render existing products and services obsolete.
- Ongoing: Integration risks associated with acquisitions and mergers.
Growth Opportunities
- Expansion in Genomic Services: Revvity can capitalize on the growing demand for genomic services by expanding its offerings in next-generation sequencing and bioinformatics. The global genomics market is projected to reach $62.9 billion by 2028, growing at a CAGR of 15.4%. Revvity's existing technologies and expertise position it well to capture a significant share of this market by offering comprehensive genomic solutions to researchers and clinicians.
- Strategic Acquisitions: Revvity can drive growth through strategic acquisitions that expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or market access, Revvity can strengthen its competitive position and accelerate revenue growth. The company has a history of successful acquisitions, and further strategic deals could significantly enhance its long-term growth prospects.
- Development of Novel Diagnostic Assays: The development and commercialization of novel diagnostic assays for early disease detection represents a significant growth opportunity. The global diagnostics market is expected to reach $125 billion by 2027. Revvity's focus on innovation and its expertise in assay development position it to capitalize on this trend by introducing new and improved diagnostic solutions.
- Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia-Pacific and Latin America, offers substantial growth potential. These regions are experiencing rapid economic growth and increasing healthcare expenditure, creating significant opportunities for Revvity's products and services. By establishing local partnerships and tailoring its offerings to meet the specific needs of these markets, Revvity can drive significant revenue growth.
- Advancements in Informatics and Software Solutions: Revvity can leverage its informatics and software capabilities to provide integrated solutions that enhance research and diagnostic workflows. The market for healthcare informatics is growing rapidly, driven by the increasing volume of data generated by research and clinical activities. By offering user-friendly and powerful software tools, Revvity can attract new customers and strengthen its relationships with existing ones.
Opportunities
- Expansion into emerging markets.
- Strategic acquisitions to expand product offerings.
- Development of new diagnostic assays and technologies.
- Increased demand for personalized medicine and genomic services.
Threats
- Economic downturns affecting research funding.
- Technological obsolescence and disruptive innovations.
- Increased competition from existing and new players.
- Changes in healthcare reimbursement policies.
Competitive Advantages
- Strong brand reputation built over decades as PerkinElmer.
- Extensive product portfolio covering multiple segments of the life sciences and diagnostics markets.
- Proprietary technologies and intellectual property.
- Established relationships with key customers and partners.
About
Revvity, Inc., formerly known as PerkinElmer, Inc., was founded in 1937 and rebranded in April 2023 to reflect its evolved focus on human health. Headquartered in Waltham, Massachusetts, Revvity operates globally, providing products, services, and solutions to the diagnostics, life sciences, and applied services markets. The company is structured into two primary segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a wide array of instruments, reagents, informatics, software, and detection technologies that enable scientists to accelerate research in life sciences. This segment also provides analytical technologies for environmental monitoring, food production, and industrial applications. The Diagnostics segment focuses on developing and marketing instruments, reagents, assay platforms, and software for the early detection of genetic disorders and infectious diseases. Revvity's products are used in screening for conditions such as Down syndrome, hypothyroidism, and various metabolic disorders. The company serves a diverse customer base, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, and government agencies. Revvity's strategic focus on innovation and customer collaboration positions it as a key player in advancing healthcare and scientific discovery.
What They Do
- Develop and manufacture instruments for life science research.
- Produce reagents and consumables for scientific experiments.
- Offer informatics and software solutions for data analysis.
- Provide diagnostic testing solutions for genetic disorders and infectious diseases.
- Offer contract research and laboratory services.
- Provide analytical technologies for environmental monitoring.
- Develop assay platforms for drug discovery and development.
Business Model
- Sale of instruments, reagents, and consumables to research institutions and diagnostic labs.
- Subscription-based revenue from software and informatics solutions.
- Service revenue from contract research and laboratory services.
- Licensing of intellectual property and technologies.
Industry Context
Revvity operates in the rapidly evolving medical diagnostics and life sciences industry. The market is driven by increasing healthcare expenditure, advancements in genomics, and the growing demand for personalized medicine. The competitive landscape includes companies like ALGN (Align Technology), CRL (Charles River Laboratories), ENSG (Ensign Group), EXAS (Exact Sciences), and GH (Guardant Health), each focusing on specific segments within the broader market. Revvity's diversified portfolio and strategic focus on innovation allow it to compete effectively across multiple segments, capitalizing on the overall industry growth trends.
Key Customers
- Pharmaceutical and biotechnology companies.
- Academic and research institutions.
- Public health authorities.
- Private healthcare organizations.
- Government agencies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $772M | $98M | $0.87 |
| Q3 2025 | $699M | $47M | $0.40 |
| Q2 2025 | $720M | $55M | $0.47 |
| Q1 2025 | $665M | $41M | $0.34 |
Source: Company filings
Chart & Info
Price Chart
Revvity, Inc. (RVTY) stock price: $96.03 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in Revvity's future, indicating that key stakeholders believe in the company's potential.
- •Community sentiment has shifted positively, with discussions highlighting innovative product developments that could drive growth.
- •Increased media coverage has spotlighted Revvity's advancements in technology, boosting its visibility and attracting interest from investors.
- •The overall market trend towards tech solutions aligns well with Revvity's offerings, positioning the company favorably in a growing sector.
Why Bear
- •Concerns over market competition have emerged, with analysts pointing out potential challenges from established players in the tech space.
- •Some community members express skepticism regarding the sustainability of recent growth, fearing it may not be backed by solid fundamentals.
- •Insider selling activity in the past raised red flags about potential confidence issues among executives, causing some investors to hesitate.
- •Recent earnings reports have not met community expectations, leading to a bearish sentiment among traders who are cautious about future performance.
Latest News
-
Roku To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga · Feb 3, 2026
-
Earnings Scheduled For February 2, 2026
benzinga · Feb 2, 2026
-
Earnings Scheduled For October 27, 2025
benzinga · Oct 27, 2025
Technical Analysis
Rationale
AI-generated technical analysis for RVTY including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Revvity, Inc. (RVTY) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for RVTY.
Make a Prediction
Set your price target for Revvity, Inc. (RVTY), choose a timeframe, and track your prediction accuracy.
Current price: $96.03
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RVTY.
Price Targets
Wall Street price target analysis for RVTY.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 3.6% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 8/100
Gross margin at 54.8% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of -$64.05M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates RVTY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Revvity, Inc. do?
Revvity, Inc. is a global provider of products, services, and solutions to the diagnostics, life sciences, and applied services markets. The company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, and software for life science research and industrial applications. The Diagnostics segment offers diagnostic testing solutions for genetic disorders and infectious diseases. Revvity's business model focuses on providing innovative solutions to help its customers improve human health and the environment.
Is RVTY stock a good buy?
RVTY stock presents a mixed investment picture. The company's strong market position, diverse product portfolio, and growth opportunities in genomics and diagnostics are positive factors. However, the high P/E ratio of 47.59 suggests that the stock may be overvalued. Investors should consider the company's growth prospects, competitive landscape, and potential risks before making an investment decision. A balanced approach, considering both the potential upside and downside, is warranted.
What are the main risks for RVTY?
The main risks for RVTY include economic downturns affecting research funding, regulatory changes impacting pricing and reimbursement, competition from larger and more specialized players, technological obsolescence, and integration risks associated with acquisitions. A significant portion of Revvity's revenue is tied to research and development spending, which can be sensitive to economic conditions. Additionally, changes in healthcare regulations and reimbursement policies could negatively impact the company's profitability. Competition in the life sciences and diagnostics markets is intense, requiring Revvity to continuously innovate and differentiate its offerings.
Is RVTY a good stock to buy?
Whether RVTY is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the RVTY MoonshotScore?
The MoonshotScore for RVTY is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is RVTY data updated?
RVTY stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to RVTY is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for RVTY?
Growth catalysts for Revvity, Inc. (RVTY) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Revvity, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are RVTY's main competitors?
Revvity, Inc. (RVTY) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether RVTY has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about RVTY?
Wall Street analyst coverage for RVTY includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is RVTY's market cap?
Market capitalization (market cap) for RVTY is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows RVTY's current market cap alongside enterprise value and other valuation metrics.
How has RVTY stock performed recently?
RVTY's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing RVTY's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in RVTY?
Key risk categories for RVTY include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures RVTY's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling RVTY?
Insider trading activity for RVTY tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is RVTY a good stock for beginners?
Revvity, Inc. (RVTY) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is RVTY for first-time investors?
Every stock carries risk, including Revvity, Inc. (RVTY). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like RVTY.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update. Financial metrics based on the most recent available data.